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Summary.-Sensitivity to human encephalitogenic factor (EF) was measured in 70
cancer patients, in 34 patients with various non-malignant diseases and in 18
healthy volunteers, using the macrophage migration inhibition (MMI) test.
Sensitization was demonstrated in 44/70 (63%) of the cancer patients, in 11/34 (32%)
of the patients with non-malignant conditions and in one (5%) of the healthy individ-
uals. No significant difference was seen in the frequency of demonstrable sensitivity
with clinical stage of disease in cancer patients.
Autologous serum from cancer patients had the ability to abrogate EF-mediated
migration inhibition in 22/30 sensitized individuals. This blocking occurred with a
similar frequency in all 3 clinical stages of cancer. Autologous serum from patients
with non-malignant disease caused abrogation of EF-mediated migration inhibition
in 4/11 sensitized individuals, whilst none of the healthy control individuals showed
any significant change in the migration index in the presence of autologous serum.
Homologous serum from patients with carcinoma of the breast or lung with and
without autologous blocking activity and serumfrom ahealthyindividual were tested
against lymphocytes from patients with various tumour types with the MMI test. Of
11 patients tested in the absence of serum, 8 (73%) showed significant migration
inhibition with EF, whilst serum from patients with carcinoma of the lung or breast
with autologous blocking activity abolished migration inhibition with EF in all 8
individuals with the former and in 6 with the latter, regardless of the tumour type
from which the lymphocytes under test were derived. Homologous serum from both
a carcinoma of the lung and breast without autologous blocking activity did not
abolish migration inhibition with EF, except with the latter in one patient with a
carcinoma of the lung.
A DELAYED hypersensitivity response to
encephalitogenic factor (EF), a small
polypeptide derived from the myelin
sheath of human and animal brain tissue,
has been reported in a number of human
pathological conditions, notably in malig-
nant disease. The nature and significance
of such sensitivity in neoplastic disease is
uncertain, though it seems possible that
this represents immunological cross-
reactivity between EF and neoantigen(s)
appearing on the tumour-cell surface. In
support of this, Caspary and Field (1971)
have shown that lymphocytes from cancer
patients interact specifically with EF and
2
a basic protein extracted from human
cancer tissue termed cancer basic protein
(CaBP) in the macrophage electrophoretic
mobility (MEM) test. Further investiga-
tions have shown the two proteins to be
very similar chemically (Carnegie, Caspary
and Field, 1973; Dickinson, Caspary and
Field, 1973) and to be immunologically
cross-reactive (Coates and Carnegie, 1975;
McDermott, CasparyandDickinson, 1974).
An alternative explanation to account for
the appearance of EF sensitivity in both
malignant and non-malignant disease was
proposed by Mitchell (1973), who stated
that tissue damage and necrosis due toD. J. FLAVELL AND C. W. POTTER
neoplasm or inflammatory conditions
might result in the release of a normal
tissue component which in the free state
becomes capable of immunizing the host.
Sensitivity to EF in cancer patients
appears ubiquitous when measured in the
MEM test (Caspary and Field, 1971;
Goldstone, Kerr and Irvine, 1973;
Pritchard et al., 1973); moreover, the claim
has been made that the MEM test can
discrminate between patients with early
and advanced cancer (Field and Caspary,
1972). However, results with the macro-
phage migration inhibition (MMI) test are
not so encouraging, with only about 70%
of cancer patients tested showing a
response to EF (Shelton, Potter and Carr,
1975; Singer et al., 1975; Light, Preece and
Waldron, 1975). The present study was
designed to investigate the incidence of
EF sensitivity as measured with the MMI
test in 3 groups of cancer patients (early
disease, moderate disease and advanced
disease) in patients with non-malignant
diseases and in healthy individuals. In
addition, the effects of autologous and/or
homologous serum upon EF-mediated
migration inhibition were investigated in
some ofthese individuals.
MATERIALS AND METHODS
Patients.-Seventy cancer patients attend-
ing Weston Park Hospital as inpatients were
selected for study; none were receiving
radiotherapy or chemotherapy at the time,
though many had received previous treat-
ment, including surgical removal of tumour
mass. Each patient was staged on clinical
and investigative evidence according to the
following convention:
Stage I Evidence of primary tumour only.
Stage II Evidence of primary tumour with
spread to local tissue and/or local
draining lymph nodes.
Stage III Evidence ofmetastatic disease with
deposits far from the site of
primary tumour.
Those patients presenting as borderline
between stages were included in the more
advanced stage. The group had a mean age of
49 years with a spread from 15 to 80 years. A
group of 34 patients with various non-
malignant diseases was also studied; these
were as follows: 7 with chronic bronchitis, 6
with simple epidermal warts, 8 with multiple
sclerosis, 2 with Parkinson's disease, 3 with
cerebral vascular accidents, 1 with peripheral
neuropathy, cause unknown, 1 with a brain-
stem lesion, 1 with weakness of the lower
limbs, causeunknown, 1 withencephalopathy,
3 with systemic lupus erythematosus and 1
with polymyositis. This group had a mean age
of46 years with a spread from 21 to 69 years.
A total of 18 healthy individuals drawn from
laboratory and hospital medical staff were
also studied. This group had a mean age of42
years with a spread from 19 to 59 years.
Preparation of encephalitogenic factor.-
Encephalitogenic factor was prepared by the
method ofDr J. P. Dickinson (personal com-
munication). Human brain obtained within
3 h of death was stripped of membranes and
the white matter dissected free. Myelin was
separated from the white matter by high-
speed centrifugation in 2M sucrose overlaid
with 0-32M sucrose and defatted with ice-cold
acetone. The defatted tissue was resuspended
in 0-05M HCl and stirred in the cold for 1 h
after which the suspension was clarified by
centrifugationandneutralized bythe addition
ofdiethylaminoethyl cellulose (DEAE) in the
base form. The cellulose was removed by
filtration andthe clearfiltratedialyzedagainst
water, recentrifuged and freeze-dried to give
a white powder. Preparations made in this
way were stored at -20°C. EF made by this
method was capable of inducing allergic
encephalomyelitis in 75-100% of guinea-pigs
when injected into the footpads with Freund's
complete adjuvant.
Moftp1ha,q migration inhibition test.-
Twenty ml of venous blood was collected
from each individual under study and 10 ml
placed into a lithium heparin sample tube
(Searle Diagnostics, Wycombe, England) and
10 ml into a plain glass tube. Lymphocytes
were harvested from the heparinized blood by
the Ficoll-Triosil technique of Pritchard et al.
(1973). Lymphocytes obtained in this way
were washed x 3 in TC199 (Wellcome Re-
agents Ltd., Beckenham, England) and
stored at 40C in TC199 containing 10% heat-
inactivated foetal calf serum (FCS) until use.
Peritoneal exudate cells (PEC) were induced
in Hartley guinea-pigs (200-400 g) by i.p.
stimulation with 10 ml of liquid paraffin, and
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collected and processed as described previous-
ly (Rees and Potter, 1973).
Lymphocytes and PEC were mixed to give
a final concentration of 2-0 x 106 and I 0 x
107 cells/ml respectively in TC199. This
suspension was drawn into lO,ul microcaps
(Drummond Scientific Co., USA.) and sealed
at one end with Cristaseal (Hawksley and
Sons Ltd., Lancing, England) and centrifuged
at 1500 g for 5 min. The tubes were cut at the
cell-fluid interface and fixed in the appro-
priate wells ofamigration plate (Sterilin Ltd.,
Teddington, England) with a spot of silicone
grease. Incubations were conducted in TC199
containing 10% heat-inactivated FCS and EF
at a concentration of 100 ltg/ml. Duplicate
control wells were set up without EF. Two
wells each containing 3 capillary tubes were
set up for each treatment. Every well was
sealed with a glass coverslip fixed with
silicone grease and incubated at 37°C after
gassing with a mixture of 5%C02/95% air.
The migration fans were drawn after 24h
incubation, with the aid of a projection
microscope, and the areas measured by
planimetry. The percentage inhibition of
macrophage migration with EF was calcula-
ted from the following formula:
% inhibition=100x
[l Area ofmigration with EF
1 Area ofmigration without EF J
The significance of migration inhibition was
assessed using Student's t test. A level of
P<0 01 was considered as significant.
TABLE I.-MMI by Lymphocytes from
Cancer Patients* in the Presence of En-
cephalitogenic Factor
Disease No. No. (%) showing signiificant





* 16 carcinomas of the lung, 4 carcinomas of the
larynx, 14 carcinomas of the breast, 7 carcinomas of
the cervix, 4 lymphomas, 3 basal-cell carcinomas, 5
carcionomas of the bladder, 2 carcinomas of the
ovary, 2 malignant melanomas, 2 carcinomas of the
endometrium, 1 carcinoma of the tongue, 1 carcin-
oma of the stomach, 1 carcinoma of the thyroid, 1
carcinoma of the lip, 1 carcinoma of the rectum, 1
carcinorna of the oesophagus, 1 carcinoma of the
vagina-urethra, 1 carcinoma of the ethmoid, 1
lymphosarcoma, 1 prostatic sarcoma and 1 leiomyo-
sarcoma of the jejunum.
Serum inhibition of EF-mediated migration
inhibition.-Ten ml of venous blood collected
from each individual under test was allowed
to clot at room temperature for 1 h and was
centrifuged at 1500 g for 10 min. The serum
was harvested from the tube and heat-inacti-
vated at 56°C for 30 min. The effects of
autologous serum drawn from the same
patient, or homologous serum drawn from
different patients with the same or different
tumour types, upon EF-mediated migration
inhibition were studied by including the
serum under investigation in a duplicate set
of wells at a 10% concentration with and
without EF.
RESULTS
Sensitization to EF in cancer patients and
controls
A total of 70 individuals with malignant
disease were tested for sensitivity to EF
with the MMI test. The results are shown
in Table I and in Fig. 1. A significant
inhibition of macrophage migration
(P<001) with EF was seen in 44 of
these patients. Division of this group
into 3 clinical stages (I-III) showed that
the frequency of sensitivity to EF
was about the same in all 3 (Table I).
Patients with non-malignant diseases were
divided into individuals with chronic
bronchitis, warts, multiple sclerosis, neuro-
logical conditions a.nd others. The results
for 34 individuals tested with non-
malignant disease are shown in Table II
and Fig. 2. Significant migration inhibition
with EF was seen in 11 of these patients,
the highest frequency of sensitivity being
observed in 9 patients with various
neurological conditions, among whom 4
showed sensitivity, and the lowest frequ-
encyin agroup of6individualswith simple
epidermal warts, among whom one showed
significant migration inhibition. Lympho-
cytes from 18 healthy individuals were
also tested for sensitivity to EF with the
MMI test. Theresults areshownin TableII
and inFig. 2. Ofthe 18 tested, one showed
significant migration inhibition with EF.
Effects ofautologous serum
The effects ofautologous serum included




































FIG. 1.-Percentage inhibition ofmacrophage
migration (MMI) by lymphocytes from
cancer patients in the presence ofencepha-
litogenic factor.
in a duplicate set of control and EF-
containing wells were investigated in 53
cancer patients, in 34 patients with non-
malignant disease and in 18 healthy
individuals. Theresults obtainedforthe 53
cancer patients tested in the absence and
presence ofautologous serum are shown in
FIG. 2.-Percentage inhibition ofmacrophage
migration (MMI) by lymphocytes from
patients with non-malignant disease and
from healthy individuals in the presence of
encephalitogenic factor.
t 3 patients with systemic lupus erythe-
matosus and one patient with polymyositis.
TABLE II.-MMI by Lymphocytesfrom Patients with Non-malignant Diseases andfrom


















* 2 Parkinson's disease, 3 cerebral vascular accidents, 1 encephalopathy, 1 peripheral neuropathy
(cause unknown), 1 weakness of the lower limbs (cause unknown) and 1 brain-stem lesion.
t 1 polymyositis and 3 systemic lupus erythematosus.
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TABLE III.-MMI by LymphocytesfromCancerPatients* in the Presenceof Encephalito-
genic Factor, with and without Autologous Serum
No. (%) showing significant MMI (P<0*01)
Disease stage No. tested Without serum With autologous serum
I 17 9(53) 2(12)
II 14 9(64) 3(21)
III 22 13(59) 4(18)
Total 53 31(58) 9(17)
* 11 carcinomas of the lung, 9 carcinomas of the breast, 7 carcinomas of the cervix, 3 carcinomas of the
bladder, 2 carcinomas ofthe ovary, 2 basal cell carcinomas, 2 carcinomas of the larynx, 2 malignant melano-
mas, 3 lymphomas, 1 carcinoma of the tongue, 1 carcinoma ofthe endometrium, 1 carcinoma ofthe rectum,
1 carcinomna of the lip, 1 carcinoma of the thyroid, 1 carcinoma of the stomach, 1 carcinoma of the vagina-
urethra, 1 carcinoma of the ethmoid, 1 carcinoma of the oesophagus, 1 leiomyosarcoma of the jejunum, 1
prostatic sarcoma and 1 lymphosarcoma.
TABLE IV.-MMI by Lymphocytes from Patients with Non-maligant Diseases andfrom



















No. (% ) showing significant MMI (P<0- 01)










TABLE V.-The Effects ofHomologous Serum on MMI by LymphocytesfromPatients with
Various Tumour Types
















Homologous serum with (+) or without (-) autologous
blocking from:









Table III. Of these, 31 patients showed
significant migration inhibition with EF in
the absence of autlogous serum, but this
was abolished in 22 ofthem in the presence
ofautologous serum. Division ofthe cancer
patients into 3 clinical stages (1-111) did
not show any significant difference in









Autologous serum from 34 individuals
with various non-malignant conditions
blocked EF-mediated migration inhibition
in 4/11 patients showing significant migra-
tion inhibition with EF (Table IV).
Serum-blocking activity in this group
occurred in 2 patients with Parkinson's
disease, one patient with warts and one
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Autologous serum from healthy individ-
uals produced no significant change in
macrophage migration from that in the
absence of autlogous serum (Table IV).
Effects ofhomologous serum
Serum from a healthy individual, 2
patients with carcinoma of the lung (one
with and one without autologous blocking
activity) and 2 patients with carcinoma of
the breast (one with and one without
autologous blocking activity) were tested
against lymphocytes from 4 patients with
carcinoma of the breast, 3 with carcinoma
of the lung, 2 with carcinoma of the blad-
der, 1 with carcinoma of the larynx and 1
with a basal-cell carcinoma of the scalp,
for evidence of blocking activity by
homologous serum. The results are shown
in Table V. Of the 11 cancer patients with
the MMI test in the absence of serum, 8
showed significant migration inhibition
with EF. In the presence of normal
serum, all 8 retained significant migration
inhibition with EF. When serum from a
patient with carcinoma ofthe lung without
autologous blocking activity was used, all
8 patients retained demonstrable sensitiv-
ity. However, serum from a carcinoma of
the lung with autologous blocking activity
abolished EF-mediated migration inhibi-
tion in all 8 patients, regardless of the
tumour type from which the lymphocytes
under test were derived (Table V).
Serum from a carcinoma of the breast
without autologous blocking activity abol-
ished EF-mediated migration inhibition in
one patient with a carcinoma of the lung,
whilst serum from a carcinoma of the
breast with autologous blocking activity
abolished EF-mediated migration inhibi-
tion in 6/8 sensitized individuals.
DISCUSSION
The results of the present study for
lymphocyte sensitivity to EF in malignant
and non-malignant disease agree well with
those of other workers using the same
techniques (Shelton et al., 1975; Light et
al., 1975; Singer et al., 1975). However, the
observed frequency ofsensitivity in cancer
is lower with the MMI test than in the
results reported for the MEM test (Field
and Caspary, 1970; Caspary and Field,
1971). This may reflect differences in
sensitivity between the two techniques,
and this has been discussed previously
(Hughes and Paty, 1971, Shelton et al.,
1975). The frequency of sensitivity to EF
in the present study was similar in all 3
clinical stages of cancer, and it is thus not
possible to discriminate between patients
with small primary tumours and extensive
metastatic disease by the MMI test.
However, Field and Caspary (1972) found
a lower degree oflymphocyte sensitivity to
CaBP in patients with advanced malignant
disease, using a standard number of
lymphocytes in the MEM test. This effect
was abolished by increasing the number of
lymphocytes under test 5- or 10-fold. Thus
the inability of the MMI test to discrimin-
ate between early and advanced malignant
disease may be due to the greater number
of lymphocytes routinely used in the test
(2 0 X 106 lymphocytes as opposed to
0.5 x 106 in the MEM test).
The present study has also confirmed
the findings of Shelton et al. (1975) that
sensitivity to EF also occurs in a number
of individuals with non-malignant condi-
tions. The high level of sensitization seen
in this study in patients with neurological
conditions suggests that conditions that
might involve nervous parenchymal des-
truction, result in the release of the EF
molecule from the intraperiod line of
lamellar myelin (Dickinson et al., 1970)
and subsequent sensitization. Alternative-
ly, EF sensitivity may prove to be a
primary factor in some disease processes.
For instance, the histological appearance
of the lesions found in the central nervous
system of patients with multiple sclerosis
suggests an active immunological process
(Nilsson, 1972). Indeed it may be that a
proportion of the carcinomatous neuro-
pathies, sometimes associated with de-
mvelination (Schlaepfer, 1974) observed
in a small number of cancer patients, may
be a secondary pathological process
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brought about by the generation of auto-
aggressive lymphocytes by neoantigen(s)
on the tumour-cell surface and immuno-
logically cross-reactive with EF or an EF-
like molecule in the central nervous
system.
Abolition of EF-mediated migration
inhibition by autologous serum was seen in
a large proportion of the cancer patients
studied, and occurred with a similar
frequency in all 3 clinical stages. Moreover,
serum which abolished the lymphocyte
response to EF in the autologous situation
also abolished the EF response oflympho-
cytes from patients with different tumour
types. Serum abolition of the lymphocyte
response to EF was also seen in 4/11
sensitized individuals with non-malignant
conditions. This serum effect thus differs
markedlyfrom serum blocking phenomena
observed in cancerpatients and thought to
be mediated by free circulating antigen or
antigen-antibody complexes (Currie and
Basham, 1972; Currie, 1973; Sj6gren et al.,
1971). Here, serum blocking activity
correlates well with the extent of the
disease (Currie, 1973; Bray and Holt,
1975) the highest titres being found in
advanced disease, and also proves to be
specific for the tumour type from which
the serum was derived (Hellstrom et al.,
1971). It seems likely that the serum effect
seen in the present study might be closely
akin to the serum lymphocyte-depressive
factor described by Field and Caspary
(1972) and thought to be dueto the alpha2
macroglobulin component ofserum (Ford,
Caspary and Shenton, 1973).
In conclusion, it thus seems that the
MMI test in its present form, used to
measure EF sensitivity and associated
serum inhibitory activity, is unable to
discriminate between patients with early
and advanced malignant disease.
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